Clinical Pharmacogenomics of Thiopurine S-methyltransferase

Title: Clinical Pharmacogenomics of Thiopurine S-methyltransferase

Volume: 1 Issue: 1

Author(s): Shufeng Zhou

Affiliation:

Keywords: Thiopurinemethyltransferase, Thiopurine, Single nucleotide polymorphism (SNP), Genetic polymorphism, toxicity

Abstract: Thiopurine methyltransferase (TPMT) catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine (6-MP), thioguanine and azathioprine (AZA). These drugs are used to treat conditions such as acutelymphoblastic leukemia, inflammatory bowel disease, rheumatoid arthritis, and organ transplant rejection. This reviewhighlights the polymorphisms of TPMT gene and their clinical impact on the use of thiopurine drugs. To date, there are 18known mutational TPMTalleles. The three main TPMT alleles, namely TPMT *2, *3A and *3C, account for 80 - 95% ofthe intermediate and low enzyme activity. The TPMT gene exhibits significant genetic polymorphisms among all ethnicgroups studied. Patientswho inherited very low levels of TPMT activity are at greatlyincreased risk for thiopurine-induced toxicity such as myelosuppression,when treated with standard doses of these drugs, while subjectswith very highactivity may be undertreated. Moreover, clinical drug interactions may occur due to TMPT induction or inhi bition.Identification of the TPMTmutant alleles allows physicians to tailor the dosage of the thiopurine drugs to the genotype ofthe patient or to use alternatives, improving therapeutic outcome

Cite this article as:

Zhou Shufeng, Clinical Pharmacogenomics of Thiopurine S-methyltransferase, Current Clinical Pharmacology 2006; 1 (1) . https://dx.doi.org/10.2174/157488406784111627